High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Blast crisis remains a significant challenge in managing chronic myeloid leukemia (CML).
• The role of additional chromosomal abnormalities (ACAs) in predicting early blastic transformation and guiding treatment timing is not fully understood.
• Philadelphia-chromosome-positive (Ph+) CML patients treated with imatinib are the focus of this investigation.

Purpose of the Study:

• To investigate whether ACAs can enable earlier recognition of imminent blastic proliferation in CML.
• To determine if ACAs facilitate a timelier change of treatment in Ph+ CML patients.
• To analyze the impact of high-risk and low-risk ACAs on survival at different blast levels.

Main Methods:

• Analysis of 1,510 imatinib-treated Ph+ CML patients from the CML-study IV randomized trial.
• Categorization of ACAs into high-risk and low-risk groups based on their impact on survival.
• Utilizing a Cox model to link the presence of ACAs with different blast levels (1-30%) and survival outcomes.

Main Results:

• 8.1% of patients (123/1510) displayed ACA/Ph+, with 91 classified as high-risk.
• High-risk ACAs significantly increased the hazard to die at low blast levels (1-15%) compared to no ACAs (hazard ratios: 3.65 in blood, 6.12 in marrow).
• No significant effect of ACAs on mortality was observed at higher blast levels (20-30%).

Conclusions:

• High-risk ACAs at low blast counts can identify end-phase CML earlier than current diagnostic systems.
• Earlier identification of disease progression through ACAs may lead to improved mortality outcomes with timely treatment adjustments.
• Continued cytogenetic monitoring is recommended for CML patients exhibiting signs of progression or unsatisfactory response to therapy.